Nkarta breaks silence on CAR-NK therapy for AML, shares fall

Nkarta hopes using a different chemotherapy regimen ahead of dosing its CAR-NK cell therapy will lead to better results in acute myeloid leukemia patients whose cancer continued to grow after previous treatment options.

In its first update on NKX101 since April 2022, Nkarta presented data from two groups of…
Click here to view original post